Full Year 2025 Trading Update

Summary by AI BETAClose X

Diaceutics PLC expects to report full-year 2025 revenues of £38.5 million, a 20% increase, with constant currency growth of 24%, and anticipates returning to profitability with Adjusted EBITDA exceeding analyst consensus estimates. The company achieved a record order book of at least £36.8 million and Annual Recurring Revenue (ARR) of at least £20.3 million, alongside a 12% increase in customer therapeutic brands to 95. Diaceutics also secured a second PMx commercialisation partnership and an additional top 10 global pharma customer for enterprise-wide engagement, and forecasts 25% revenue growth for FY 2026.

Disclaimer*

Companies

Diaceutics (DXRX)
UK 100

Latest directors dealings